Status:
SUSPENDED
The Impact of Rosiglitazone on Regression of Atherosclerosis
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Science and Technology Council, Taiwan
Conditions:
Diabetes Mellitus, Atherosclerosis
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
Cardiovascular events are the leading cause of death in developed countries worldwide, including Taiwan. The disruption of atherosclerotic plaques and the subsequent formation of thrombi are currently...
Detailed Description
The early detection of vulnerable plaques is clinically important for risk stratification and also to provide early treatment.Inflammation is important in the both pathogenesis and outcome of atherosc...
Eligibility Criteria
Inclusion
- Type II DM patients who are aged 50 to 80 year-old with HbA1c between 7.0 to 10.0 %
- Under ≤ 2 kinds of anti-diabetic drugs.
Exclusion
- Insulin use
- Patients who receive any PPARγ agonist in recent one year.
- Women of child-bearing potential are excluded (i.e. menopausal women or post-hysterectomy women are included in this study) due to radiation exposure in this study.
- Significant concomitant disease such as active infection, malignancy, hepatic or renal dysfunction at the time of enrollment (i.e. T-Bil \> 3 mg/dl，ALT \> 2.5 times the upper limit of normal range and Creatinine \> 3 mg/dl in our hospital).
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00166803
Start Date
June 1 2005
Last Update
January 5 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 10012